NuVasive’s MaXcess Retractor Published Study in the Journal of Neurosurgery: Spine Further Validates Prone, Single-Position Lateral Interbody Fusion

October 5, 2020

Results of the study, “Single-position prone lateral approach: cadaveric feasibility study and early clinical experience,” in The Journal of Neurosurgery: Spine, which features NuVasive’s MaXcess retractor and further validates prone, single-position lateral interbody fusion was announced today.

“As the global leader in lateral spine surgery, NuVasive remains committed to developing comprehensive, procedural solutions that provide a truly patient-specific and optimized surgical outcome,” said Massimo Calafiore, senior vice president and general manager of NuVasive’s spine business unit. “This study adds to the growing body of evidence validating the NuVasive MaXcess retractor’s ability to perform lateral surgery in a variety of approaches, including prone position. Further, it highlights the utility of this approach, as well as its limitations, as not all patients were able to be treated in the prone position, and underscores the value of NuVasive’s X360 system—which offers a complete solution for our surgeon partners.”

The paper details a two-part study of prone, single-position lateral interbody fusion: the first provides cadaveric feasibility data to the lateral approach with the patient in the prone position, and the second explores the initial clinical experience of prone, single-position lumbar interbody fusion at two centers. A total of eight levels were treated in the cadaveric specimens, without any visceral, vascular or endplate violations noted. In the clinical series, 11 of 12 patients were able to be treated with prone, single-position lateral interbody fusion successfully, with no endplate violations or resultant subsidence. The one patient who could not have a successful prone, single-position lateral interbody fusion was converted to a single-position lateral interbody fusion procedure without incident. This study builds upon previous literature validating the prone position using NuVasive’s MaXcess retractor, a key tool in the Company’s X360™ system, and represents the largest clinical series published to date describing outcomes of prone position for a lateral approach. The authors concluded that prone positioning, in select patients, is a safe and reproducible alternative that can increase efficiency and decrease operative time.

“Prone positioning for a lateral approach presents an exciting opportunity for streamlining surgical access to the lumbar spine and facilitating a more efficient surgical solution with potential clinical and economic advantages for certain patients,” said Juan Uribe, MD, chief of the division of spinal disorders at Barrow Neurological Institute in Arizona. “As a long time XLIF user, I am grateful for NuVasive‘s leadership in developing single-position procedural technologies that support a variety of positions and span the entire patient care continuum.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version